Why the study?
Differences in hypertensive ESRD incidence between populations and families indicate genetic determinants influence disease onset and progression, prompting review of genetic variants, mechanisms, and therapeutic targets.
Design
Review
Authors
Loading...
Genetic variants may inform hypertensive ESRD risk; leaves open validation before clinical or therapeutic application.
Genetic variants in specific genes (e.g., UMOD, MYH9, APOL-1) contribute to the susceptibility of hypertension-induced kidney disease, offering potential novel targets for individualized treatment.
Zhang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: